The present invention relates generally to antibody-drag conjugates (ADCs). In particular,the invention relates to ADCs which comprise an antibody or antigen-binding fragmentthereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated tomonomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody- drug conjugate has a PC-3 cell to C4-2 or LNCaP cell selectivity of at least 250. Theinvention also relates, in part, to compositions of and methods of using the ADCs. Themethods provided include, for example, methods for treating a PSMA-mediated disease.
